Cargando…

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains to a common cause of tumor mortality worldwide and represents the most common type of lethal hepatic malignancy. The incidence of HCC is swiftly increasing in western countries and southeast Asia. Despite poor prognosis, traditional treatments for advanced HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Xinlun, Wang, Shupeng, Niu, Chunyuan, Ji, Bai, Liu, Yahui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432969/
http://dx.doi.org/10.1177/1533033820947486
_version_ 1783571915408932864
author Dai, Xinlun
Wang, Shupeng
Niu, Chunyuan
Ji, Bai
Liu, Yahui
author_facet Dai, Xinlun
Wang, Shupeng
Niu, Chunyuan
Ji, Bai
Liu, Yahui
author_sort Dai, Xinlun
collection PubMed
description Hepatocellular carcinoma (HCC) remains to a common cause of tumor mortality worldwide and represents the most common type of lethal hepatic malignancy. The incidence of HCC is swiftly increasing in western countries and southeast Asia. Despite poor prognosis, traditional treatments for advanced HCC appear to be minimally effective or even useless since patients are usually diagnosed in the advanced stage of disease. In recent years, immune checkpoint blockade has shown promising results in multiple pre-clinical and clinical trials of different solid tumors, including advanced HCC. Novel drugs targeting immune checkpoints, such as nivolumab (anti-PD-1), durvalumab (anti-PD-L1), and tremelimumab (anti-CTLA-4) have been shown to be highly effective and relatively safe in monotherapy or in combination treatment of advanced liver cancer. Unlike other immunotherapies, this approach can rouse human anti-tumor immunity by relieving T-cell exhaustion and inhibiting the evasion of HCC by blocking co-inhibitory signaling transduction accurately. In this review, we will provide current knowledge of several major immune checkpoints and summarize recent data from clinical trials that applied immune checkpoint inhibitors alone or in combination. In addition, this review will discuss the limitations and future prospective of immune checkpoint-targeted therapy for advanced HCC.
format Online
Article
Text
id pubmed-7432969
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74329692020-08-27 Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma Dai, Xinlun Wang, Shupeng Niu, Chunyuan Ji, Bai Liu, Yahui Technol Cancer Res Treat Review Hepatocellular carcinoma (HCC) remains to a common cause of tumor mortality worldwide and represents the most common type of lethal hepatic malignancy. The incidence of HCC is swiftly increasing in western countries and southeast Asia. Despite poor prognosis, traditional treatments for advanced HCC appear to be minimally effective or even useless since patients are usually diagnosed in the advanced stage of disease. In recent years, immune checkpoint blockade has shown promising results in multiple pre-clinical and clinical trials of different solid tumors, including advanced HCC. Novel drugs targeting immune checkpoints, such as nivolumab (anti-PD-1), durvalumab (anti-PD-L1), and tremelimumab (anti-CTLA-4) have been shown to be highly effective and relatively safe in monotherapy or in combination treatment of advanced liver cancer. Unlike other immunotherapies, this approach can rouse human anti-tumor immunity by relieving T-cell exhaustion and inhibiting the evasion of HCC by blocking co-inhibitory signaling transduction accurately. In this review, we will provide current knowledge of several major immune checkpoints and summarize recent data from clinical trials that applied immune checkpoint inhibitors alone or in combination. In addition, this review will discuss the limitations and future prospective of immune checkpoint-targeted therapy for advanced HCC. SAGE Publications 2020-08-17 /pmc/articles/PMC7432969/ http://dx.doi.org/10.1177/1533033820947486 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Dai, Xinlun
Wang, Shupeng
Niu, Chunyuan
Ji, Bai
Liu, Yahui
Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
title Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
title_full Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
title_fullStr Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
title_full_unstemmed Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
title_short Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
title_sort overview of current progress in immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432969/
http://dx.doi.org/10.1177/1533033820947486
work_keys_str_mv AT daixinlun overviewofcurrentprogressinimmunecheckpointinhibitortherapyforadvancedhepatocellularcarcinoma
AT wangshupeng overviewofcurrentprogressinimmunecheckpointinhibitortherapyforadvancedhepatocellularcarcinoma
AT niuchunyuan overviewofcurrentprogressinimmunecheckpointinhibitortherapyforadvancedhepatocellularcarcinoma
AT jibai overviewofcurrentprogressinimmunecheckpointinhibitortherapyforadvancedhepatocellularcarcinoma
AT liuyahui overviewofcurrentprogressinimmunecheckpointinhibitortherapyforadvancedhepatocellularcarcinoma